Dutch biotech company announces strategic expansion into premium healthcare markets with planned clinics in Lugano, Dubai, and Miami

Dutch biotechnology company Celljevity is embarking on an ambitious global expansion strategy with plans to establish flagship treatment centers in Switzerland, Dubai, and Miami by 2025. The announcement marks a significant milestone in the company’s evolution from clinical research to commercial therapy delivery, positioning its breakthrough Prometheus Cell technology for worldwide patient access.

The expansion strategy targets premium healthcare markets where patients seek cutting-edge treatments for degenerative diseases and aging-related conditions. Led by entrepreneur Diederik van der Reijt, Celljevity’s global network will deliver the company’s revolutionary cellular reprogramming therapy to international patients while establishing the infrastructure necessary for broader market penetration.

The planned Lugano clinic, scheduled to launch in Q1 2025, will serve as the European flagship for Celljevity’s operations, followed by Dubai (Q4 2025) and Miami (Q4 2025) locations. Each center will offer the full range of the company’s cellular therapies, including treatments for autoimmune diseases, neurodegenerative conditions, and orthopedic applications.

Switzerland: Gateway to European Markets

The selection of Switzerland as Celljevity’s European headquarters reflects the country’s status as a global center for medical innovation and premium healthcare services. Switzerland’s advanced healthcare infrastructure, favorable regulatory environment, and concentration of high-net-worth individuals seeking cutting-edge treatments make it an ideal launch market for breakthrough cellular therapies.

The Lugano flagship clinic will showcase Celljevity’s complete treatment portfolio, from diagnostic services through comprehensive cellular regeneration protocols. The facility will feature state-of-the-art cell processing laboratories, enabling on-site preparation of patient-specific Prometheus Cells using the company’s proprietary reprogramming technology.

Switzerland’s proximity to major European population centers positions the clinic to serve patients from across the continent, while the country’s reputation for medical excellence provides credibility that could facilitate broader European market entry. The Swiss healthcare system’s emphasis on personalized medicine aligns closely with Celljevity’s autologous treatment approach.

Dubai: Strategic Hub for Middle East and Asia

The planned Dubai clinic represents Celljevity’s entry into rapidly growing Middle Eastern and Asian healthcare markets. Dubai’s position as a global travel hub and its investment in medical tourism infrastructure make it an ideal location for serving international patients seeking advanced regenerative therapies.

The United Arab Emirates has established itself as a destination for cutting-edge medical treatments, with government support for healthcare innovation and streamlined processes for international patients. Celljevity’s entry into this market could position the company to serve patients from across the Middle East, Africa, and Asia who may have limited access to advanced cellular therapies.

Dubai’s multicultural environment and English-language healthcare services provide additional advantages for serving diverse international patient populations. The clinic will leverage the city’s advanced medical infrastructure while offering Celljevity’s full range of regenerative therapies.

Miami: Gateway to Americas Market

The Miami location strategically positions Celljevity for expansion throughout the Americas, serving both U.S. patients and international visitors seeking advanced medical treatments. Florida’s growing reputation as a center for regenerative medicine and anti-aging therapies creates a favorable environment for introducing breakthrough cellular treatments.

Miami’s large population of health-conscious, affluent residents provides a natural market for Celljevity’s longevity-focused therapies. The city’s established medical tourism industry and proximity to Latin American markets offer opportunities for broader regional expansion as regulatory approvals permit.

The clinic will also serve as a platform for potential FDA interactions and clinical development programs, supporting Celljevity’s broader strategy for obtaining U.S. regulatory approval and eventual market entry.

Technology Platform and Treatment Offerings

Each flagship clinic will offer Celljevity’s complete portfolio of cellular therapies, customized to address individual patient needs and conditions. The treatment menu includes VitaCell for autoimmune diseases, NeuroRevive for neurodegenerative conditions, ReGenova for osteoarthritis, and comprehensive anti-aging protocols utilizing Prometheus Cell technology.

The clinics will feature integrated diagnostic capabilities, including Celljevity’s ImmuneSync dual-biomarker testing for autoimmune conditions and comprehensive biological age assessments through telomere analysis. This diagnostic integration enables precise treatment customization and ongoing monitoring of therapeutic outcomes.

Manufacturing capabilities will be distributed across the network, with each clinic capable of processing patient cells using Celljevity’s proprietary reprogramming protocols. This decentralized approach reduces logistics complexity while ensuring treatment availability and quality consistency across all locations.

Premium Market Strategy and Accessibility Vision

The initial focus on premium markets reflects Celljevity’s strategy for establishing clinical credibility and generating revenue to support broader accessibility programs. Treatment pricing in flagship clinics will reflect the breakthrough nature of the technology while providing sustainable funding for continued research and development.

However, the premium market entry represents only the first phase of Celljevity’s broader vision for global healthcare transformation. The company has committed to providing its intellectual property at minimal or no cost to underserved regions, ensuring that breakthrough therapies eventually reach all populations regardless of economic status.

Revenue generated through flagship clinics will support accessibility programs, research and development, and infrastructure development in emerging markets. This sustainable approach enables commercial success while advancing the company’s humanitarian mission.

Clinical Excellence and Quality Standards

Each Celljevity treatment center will maintain the exceptional clinical standards established in the company’s research programs. All facilities will adhere to Good Manufacturing Practice guidelines, ensuring consistent quality and safety across the global network.

Staff training programs will ensure that all clinics deliver uniform treatment experiences while maintaining the personalized approach that characterizes Celljevity’s therapy. Ongoing quality monitoring and outcome tracking will support continuous improvement and regulatory compliance across all locations.

The company’s commitment to clinical excellence extends to patient selection and treatment protocols, with comprehensive screening processes ensuring optimal treatment outcomes while maintaining safety standards established in clinical trials.

Future Network Expansion

The three flagship clinics represent the foundation for a broader global treatment network that could eventually include dozens of locations worldwide. Future expansion plans target major population centers in Europe, Asia, and the Americas, with particular focus on regions where aging populations create significant demand for regenerative therapies.

Celljevity’s strategy envisions serving over 50,000 patients annually once the full network is operational, transforming the company from a research-focused organization to a global healthcare provider. This scale would position Celljevity as a leader in regenerative medicine while generating substantial revenue for continued innovation and accessibility programs.

The global network will also support continued clinical research, with each location contributing to expanded clinical databases and treatment optimization. This distributed research approach could accelerate development of next-generation therapies while building the evidence base necessary for broader regulatory approvals.

As Celljevity moves toward commercial operations, the establishment of flagship clinics represents a crucial step in translating breakthrough research into patient care. The global network will demonstrate that cellular age reversal can be delivered safely and effectively at scale, potentially inspiring broader adoption of regenerative approaches across the healthcare industry.